Drugs / LNP1265
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06379789 | Sep 2024 → Aug 2034 expected | hemophilia B | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LNP1265 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06379789 ↗ |